Global Propionic Acidemia Market

Propionic Acidemia Comprehensive Study by Type (Neonatal-Onset PA, Late-Onset PA), Application (Hospitals & Clinics, Medicinal & Pharmaceutical Stores), Treatment Type (Carnitine Supplementation, Fluid & Biotin Therapy, Hemodialysis, Peritoneal Dialysis, Strict Dietary Management, Others) Players and Region - Global Market Outlook to 2026

Propionic Acidemia Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Propionic Acidemia?
Propionic Academia (PA) is a very rare genetic disease or disorder which basically caused by dis-functionality and deficiency of propionyl-CoA carboxylase. propionyl-CoA carboxylase is a type of enzyme within human body which is responsible for breaking down of amino acids of proteins. Propionic Acidemia is categorised as Metabolic Disorder, this also leads up to build up of toxic content within the tissues as organic acids increases within body. Propionic Acidemia is mostly found in New-born infants due to faulty genes passed over by parents. The symptoms of PA may be vomiting, weak muscle tone to more severe such as seizures, coma, and even the possibly of death. Although there are no particular drugs completely treating PA, but there does exist certain therapies and passive drugs which can limit the spread and severity of PA. It is highly found in Middle East, and Europe.

The market study is broken down by Type (Neonatal-Onset PA and Late-Onset PA), by Application (Hospitals & Clinics and Medicinal & Pharmaceutical Stores) and major geographies with country level break-up.

Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Moderna Inc. (United States), Recordati S.p.A (Italy), CSL Behring (United States), HemoShear Therapeutics, Inc. (United States), BRIDGEBIO PHARMA, INC. (United States) and GeneDx, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Propionic Acidemia market by Type, Application and Region.

On the basis of geography, the market of Propionic Acidemia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Carnitine Supplementation will boost the Propionic Acidemia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2019, Moderna, Inc., one of world’s largest pharmaceutical and Biotechnology Company received FDA clearance for fast track designation for its messenger therapeutic called mRNA-3927, to treat propionic acidemia (PA). The Mrna-3927 is aimed at helping body restore dysfunctional proteins and it includes two mRNA’s consisting of PCC and LNP to treat PA., and In 2021, United States FDA has approved Carbaglu as an adjunctive treatment therapy for acute hyperammonemia which is caused primarily by PA.
Biotin has not Been Approved by FDA for Medicinal Use. According to US FDA, “Metronidazole” is used to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat infections that are proven to be caused by bacteria

Market Trend
  • Intense Research and Development in Bio-Medicine Specific to Genetic Disorders

Market Drivers
  • Rising Genetic Disorders
  • Improvement in Medical Infrastructure

Opportunities
  • Surge in Medical Insurance Coverages
  • Augmenting Awareness and Government Funding's has Created Growth Opportunities for Market

Restraints
  • High Cost of Treatment
  • Less Awareness regarding Genetic Disorders in Emerging Countries of South America & Middle East

Challenges
  • Suitability of Proper Treatment


Key Target Audience
Propionic Acidemia Treatment Providers, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Neonatal-Onset PA
  • Late-Onset PA
By Application
  • Hospitals & Clinics
  • Medicinal & Pharmaceutical Stores
By Treatment Type
  • Carnitine Supplementation
  • Fluid & Biotin Therapy
  • Hemodialysis
  • Peritoneal Dialysis
  • Strict Dietary Management
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Genetic Disorders
      • 3.2.2. Improvement in Medical Infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Suitability of Proper Treatment
    • 3.4. Market Trends
      • 3.4.1. Intense Research and Development in Bio-Medicine Specific to Genetic Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Propionic Acidemia, by Type, Application, Treatment Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Propionic Acidemia (Value)
      • 5.2.1. Global Propionic Acidemia by: Type (Value)
        • 5.2.1.1. Neonatal-Onset PA
        • 5.2.1.2. Late-Onset PA
      • 5.2.2. Global Propionic Acidemia by: Application (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Medicinal & Pharmaceutical Stores
      • 5.2.3. Global Propionic Acidemia by: Treatment Type (Value)
        • 5.2.3.1. Carnitine Supplementation
        • 5.2.3.2. Fluid & Biotin Therapy
        • 5.2.3.3. Hemodialysis
        • 5.2.3.4. Peritoneal Dialysis
        • 5.2.3.5. Strict Dietary Management
        • 5.2.3.6. Others
      • 5.2.4. Global Propionic Acidemia Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Propionic Acidemia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Recordati S.p.A (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Behring (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. HemoShear Therapeutics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BRIDGEBIO PHARMA, INC. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GeneDx, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Propionic Acidemia Sale, by Type, Application, Treatment Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Propionic Acidemia (Value)
      • 7.2.1. Global Propionic Acidemia by: Type (Value)
        • 7.2.1.1. Neonatal-Onset PA
        • 7.2.1.2. Late-Onset PA
      • 7.2.2. Global Propionic Acidemia by: Application (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Medicinal & Pharmaceutical Stores
      • 7.2.3. Global Propionic Acidemia by: Treatment Type (Value)
        • 7.2.3.1. Carnitine Supplementation
        • 7.2.3.2. Fluid & Biotin Therapy
        • 7.2.3.3. Hemodialysis
        • 7.2.3.4. Peritoneal Dialysis
        • 7.2.3.5. Strict Dietary Management
        • 7.2.3.6. Others
      • 7.2.4. Global Propionic Acidemia Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Propionic Acidemia: by Type(USD Million)
  • Table 2. Propionic Acidemia Neonatal-Onset PA , by Region USD Million (2015-2020)
  • Table 3. Propionic Acidemia Late-Onset PA , by Region USD Million (2015-2020)
  • Table 4. Propionic Acidemia: by Application(USD Million)
  • Table 5. Propionic Acidemia Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 6. Propionic Acidemia Medicinal & Pharmaceutical Stores , by Region USD Million (2015-2020)
  • Table 7. Propionic Acidemia: by Treatment Type(USD Million)
  • Table 8. Propionic Acidemia Carnitine Supplementation , by Region USD Million (2015-2020)
  • Table 9. Propionic Acidemia Fluid & Biotin Therapy , by Region USD Million (2015-2020)
  • Table 10. Propionic Acidemia Hemodialysis , by Region USD Million (2015-2020)
  • Table 11. Propionic Acidemia Peritoneal Dialysis , by Region USD Million (2015-2020)
  • Table 12. Propionic Acidemia Strict Dietary Management , by Region USD Million (2015-2020)
  • Table 13. Propionic Acidemia Others , by Region USD Million (2015-2020)
  • Table 14. South America Propionic Acidemia, by Country USD Million (2015-2020)
  • Table 15. South America Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 16. South America Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 17. South America Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 18. Brazil Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 19. Brazil Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 20. Brazil Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 21. Argentina Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 22. Argentina Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 23. Argentina Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 24. Rest of South America Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 27. Asia Pacific Propionic Acidemia, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 31. China Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 32. China Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 33. China Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 34. Japan Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 35. Japan Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 36. Japan Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 37. India Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 38. India Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 39. India Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 40. South Korea Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 41. South Korea Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 42. South Korea Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 43. Taiwan Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 44. Taiwan Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 45. Taiwan Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 46. Australia Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 47. Australia Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 48. Australia Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 52. Europe Propionic Acidemia, by Country USD Million (2015-2020)
  • Table 53. Europe Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 54. Europe Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 55. Europe Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 56. Germany Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 57. Germany Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 58. Germany Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 59. France Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 60. France Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 61. France Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 62. Italy Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 63. Italy Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 64. Italy Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 65. United Kingdom Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 68. Netherlands Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 69. Netherlands Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 70. Netherlands Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 71. Rest of Europe Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 74. MEA Propionic Acidemia, by Country USD Million (2015-2020)
  • Table 75. MEA Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 76. MEA Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 77. MEA Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 78. Middle East Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 79. Middle East Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 80. Middle East Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 81. Africa Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 82. Africa Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 83. Africa Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 84. North America Propionic Acidemia, by Country USD Million (2015-2020)
  • Table 85. North America Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 86. North America Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 87. North America Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 88. United States Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 89. United States Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 90. United States Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 91. Canada Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 92. Canada Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 93. Canada Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 94. Mexico Propionic Acidemia, by Type USD Million (2015-2020)
  • Table 95. Mexico Propionic Acidemia, by Application USD Million (2015-2020)
  • Table 96. Mexico Propionic Acidemia, by Treatment Type USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Propionic Acidemia: by Type(USD Million)
  • Table 104. Propionic Acidemia Neonatal-Onset PA , by Region USD Million (2021-2026)
  • Table 105. Propionic Acidemia Late-Onset PA , by Region USD Million (2021-2026)
  • Table 106. Propionic Acidemia: by Application(USD Million)
  • Table 107. Propionic Acidemia Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 108. Propionic Acidemia Medicinal & Pharmaceutical Stores , by Region USD Million (2021-2026)
  • Table 109. Propionic Acidemia: by Treatment Type(USD Million)
  • Table 110. Propionic Acidemia Carnitine Supplementation , by Region USD Million (2021-2026)
  • Table 111. Propionic Acidemia Fluid & Biotin Therapy , by Region USD Million (2021-2026)
  • Table 112. Propionic Acidemia Hemodialysis , by Region USD Million (2021-2026)
  • Table 113. Propionic Acidemia Peritoneal Dialysis , by Region USD Million (2021-2026)
  • Table 114. Propionic Acidemia Strict Dietary Management , by Region USD Million (2021-2026)
  • Table 115. Propionic Acidemia Others , by Region USD Million (2021-2026)
  • Table 116. South America Propionic Acidemia, by Country USD Million (2021-2026)
  • Table 117. South America Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 118. South America Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 119. South America Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 120. Brazil Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 121. Brazil Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 122. Brazil Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 123. Argentina Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 124. Argentina Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 125. Argentina Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 126. Rest of South America Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 127. Rest of South America Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 128. Rest of South America Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 129. Asia Pacific Propionic Acidemia, by Country USD Million (2021-2026)
  • Table 130. Asia Pacific Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 131. Asia Pacific Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 132. Asia Pacific Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 133. China Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 134. China Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 135. China Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 136. Japan Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 137. Japan Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 138. Japan Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 139. India Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 140. India Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 141. India Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 142. South Korea Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 143. South Korea Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 144. South Korea Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 145. Taiwan Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 146. Taiwan Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 147. Taiwan Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 148. Australia Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 149. Australia Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 150. Australia Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 154. Europe Propionic Acidemia, by Country USD Million (2021-2026)
  • Table 155. Europe Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 156. Europe Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 157. Europe Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 158. Germany Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 159. Germany Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 160. Germany Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 161. France Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 162. France Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 163. France Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 164. Italy Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 165. Italy Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 166. Italy Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 167. United Kingdom Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 168. United Kingdom Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 169. United Kingdom Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 170. Netherlands Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 171. Netherlands Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 172. Netherlands Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 173. Rest of Europe Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 174. Rest of Europe Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 175. Rest of Europe Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 176. MEA Propionic Acidemia, by Country USD Million (2021-2026)
  • Table 177. MEA Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 178. MEA Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 179. MEA Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 180. Middle East Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 181. Middle East Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 182. Middle East Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 183. Africa Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 184. Africa Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 185. Africa Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 186. North America Propionic Acidemia, by Country USD Million (2021-2026)
  • Table 187. North America Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 188. North America Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 189. North America Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 190. United States Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 191. United States Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 192. United States Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 193. Canada Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 194. Canada Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 195. Canada Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 196. Mexico Propionic Acidemia, by Type USD Million (2021-2026)
  • Table 197. Mexico Propionic Acidemia, by Application USD Million (2021-2026)
  • Table 198. Mexico Propionic Acidemia, by Treatment Type USD Million (2021-2026)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Propionic Acidemia: by Type USD Million (2015-2020)
  • Figure 5. Global Propionic Acidemia: by Application USD Million (2015-2020)
  • Figure 6. Global Propionic Acidemia: by Treatment Type USD Million (2015-2020)
  • Figure 7. South America Propionic Acidemia Share (%), by Country
  • Figure 8. Asia Pacific Propionic Acidemia Share (%), by Country
  • Figure 9. Europe Propionic Acidemia Share (%), by Country
  • Figure 10. MEA Propionic Acidemia Share (%), by Country
  • Figure 11. North America Propionic Acidemia Share (%), by Country
  • Figure 12. Global Propionic Acidemia share by Players 2020 (%)
  • Figure 13. Global Propionic Acidemia share by Players (Top 3) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Moderna Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Moderna Inc. (United States) Revenue: by Geography 2020
  • Figure 17. Recordati S.p.A (Italy) Revenue, Net Income and Gross profit
  • Figure 18. Recordati S.p.A (Italy) Revenue: by Geography 2020
  • Figure 19. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 20. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 21. HemoShear Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. HemoShear Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. BRIDGEBIO PHARMA, INC. (United States) Revenue, Net Income and Gross profit
  • Figure 24. BRIDGEBIO PHARMA, INC. (United States) Revenue: by Geography 2020
  • Figure 25. GeneDx, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. GeneDx, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Global Propionic Acidemia: by Type USD Million (2021-2026)
  • Figure 28. Global Propionic Acidemia: by Application USD Million (2021-2026)
  • Figure 29. Global Propionic Acidemia: by Treatment Type USD Million (2021-2026)
  • Figure 30. South America Propionic Acidemia Share (%), by Country
  • Figure 31. Asia Pacific Propionic Acidemia Share (%), by Country
  • Figure 32. Europe Propionic Acidemia Share (%), by Country
  • Figure 33. MEA Propionic Acidemia Share (%), by Country
  • Figure 34. North America Propionic Acidemia Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Moderna Inc. (United States)
  • Recordati S.p.A (Italy)
  • CSL Behring (United States)
  • HemoShear Therapeutics, Inc. (United States)
  • BRIDGEBIO PHARMA, INC. (United States)
  • GeneDx, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 201 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Propionic Acidemia Market Quantitative research analysis
Global Propionic Acidemia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Moderna Inc. (United States), Recordati S.p.A (Italy), CSL Behring (United States), HemoShear Therapeutics, Inc. (United States), BRIDGEBIO PHARMA, INC. (United States) and GeneDx, Inc. (United States) etc.
Analysts at AMA estimates Propionic Acidemia Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Propionic Acidemia Market Report?

Have a Query? Click Here

Other Related Reports

Ataxia-Telangiectasia Comprehensive Study by Distribution Channel (Hospital Pharmacies, Online Pharmacies), Diagnosis Type (IgA and Serum Alpha-1 Fetoprotein Levels, Genetic Testing), Treatment Type ...
$ 3350
Aplastic Anemia Treatment Comprehensive Study by Application (Adults, Kids), Disease Type (Acquired Aplastic Anemia, Inherited Bone Marrow Failure Syndromes (Inherited Aplastic Anemia)), Route of Adm...
$ 3750
Alexandrite Laser Treatment Comprehensive Study by Application (Aesthetic, Dermatology, Dentistry, Urology, Others), Indication (Vascular lesions, Pigmented lesions, Hair removal, Tattoo removal), En...
$ 3350
Fatty Acid Oxidation Disorder Comprehensive Study by Supplement Type (L-carnitine, L-carnitine, Medium Chain Triglyceride Oil), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online St...
$ 3750
Antiviral Combination Therapies Comprehensive Study by Type (Branded, Generic), Route of Administration (Oral, Intravenous), Indication (HIV, Hepatitis, Others), Drug Combination (NRTI/NNRTI, Integra...
$ 3450
Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) ...
$ 3500